Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amylyx Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 23, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 15, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
February 15, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
February 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
December 22, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
December 04, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
November 28, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
November 27, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
November 02, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium
October 19, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
October 13, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
October 10, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
October 02, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
July 12, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
June 23, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
June 15, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
May 30, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
May 11, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
May 05, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
April 20, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
April 13, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.